Xencor, Inc.

Genentech, Inc.

Rajat Varma

Matthew J Bernett

John R Desjarlais

Rumana Rashid

Christine Bonzon

Juan Diaz

Ke Liu

Suzanne Schubbert

Nargess Hassanzadeh-Kiabi

Michael Hedvat

Alex Nisthal

Gregory L Moore

Eric Chang

Katrina Bykova

Yoon Kyung Kim

Raphael Clynes

Christine Huang

Patrick Holder

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains

The present invention is directed to novel IL-15/IL-15Rα heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15Rα heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15Rα heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.

IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereof

The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.

IL-12 heterodimeric Fc-fusion proteins

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.

Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains

The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

Untargeted and targeted IL-10 Fc-fusion proteins

The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.

Engineered IL-2 Fc fusion proteins

The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties

Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.

Heterodimeric antibodies that bind CD3 and GPC3

The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.

Targeted IL-12 heterodimeric Fc-fusion proteins

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains

The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.

Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments

The present invention is directed to novel PD-1-targeted IL-15/R&#x3b1;-Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc-fusion protein and a PD-1 antigen binding domain. The PD-1-targeted IL-15/R&#x3b1;-Fc fusion proteins can be administered to a patient to treat cancer.

PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof

Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.

IL-7-FC-fusion proteins

The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.

Growing community of inventors

Monrovia, CA, United States of America

Rajat Varma